AUA2024: Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider

CME Available: https://auau.auanet.org/node/41015

At the conclusion of this activity, participants will be able to:

1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)

2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists.

3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB

4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents

5. Discuss potential future pharmacological pathways and therapies for OAB.

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Astellas